Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

Phase 2

Conditions: Coronary Artery Disease

Interventions: Drug: ticagrelor
Drug: clopidogrel

First Posted Date: 2016-09-05

Last Posted Date: 2017-02-23

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Target Recruit Count: 60

Registration Number: NCT02889549

Locations: 🇨🇳
Endothelial Function detection by brachial artery ultrasound, Harbin, China
🇺🇸
VerifyNow, San Diego, California, United States

Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

Phase 3

Completed

Conditions: Ischemic Stroke

Interventions: Drug: clopidogrel
Drug: Aspirin

First Posted Date: 2016-08-16

Last Posted Date: 2022-12-07

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 3000

Registration Number: NCT02869009

Locations: 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban
Drug: Clopidogrel
Drug: Prasugrel
Drug: Vitamin K antagonist
Drug: Ticagrelor

First Posted Date: 2016-08-15

Last Posted Date: 2020-05-06

Lead Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Target Recruit Count: 1506

Registration Number: NCT02866175

Locations: 🇺🇦
Kharkiv City Clinical Hospital #8, Kharkiv, Ukraine
🇬🇧
Altnagelvin Area Hospital, Londonderry, United Kingdom
🇬🇧
Golden Jubilee Hospital, Clydebank, United Kingdom

and more 197 locations

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

Phase 3

Completed

Conditions: Aortic Valve Stenosis
Ventricular Outflow Obstruction
Thrombosis
Heart Valve Diseases
Cardiovascular Diseases

Interventions: Drug: Acetylsalicylic acid
Drug: Clopidogrel
Drug: Rivaroxaban

First Posted Date: 2016-07-14

Last Posted Date: 2020-01-18

Lead Sponsor: ECRI bv

Target Recruit Count: 231

Registration Number: NCT02833948

Locations: 🇳🇱
Erasmus M.C, Rotterdam, Netherlands
🇸🇪
Skåne University Hospital, Lund, Sweden
🇸🇪
Karolinska University Hospital, Stockholm, Sweden

and more 22 locations

Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction

Not Applicable

Conditions: Cardiovascular Diseases

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-06-14

Last Posted Date: 2016-06-14

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 240

Registration Number: NCT02798874

Locations: 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China

Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI

Phase 4

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-06-07

Last Posted Date: 2016-06-07

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 200

Registration Number: NCT02792712

Locations: 🇨🇳
Teipei Veterans General Hospital, Taipei, Taiwan

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Procedure: Primary PCI
Drug: Tenecteplase
Drug: Clopidogrel
Procedure: Coronary angiography

First Posted Date: 2016-05-19

Last Posted Date: 2024-10-04

Lead Sponsor: KU Leuven

Target Recruit Count: 609

Registration Number: NCT02777580

Locations: 🇨🇱
Hospital de Tocopilla, Tocopilla, Chile
🇨🇱
Hospital Regional de Antofagasta, Antofagasta, Chile
🇷🇸
Institute for cardiovascular diseases Dedinje, Cardiovascular research sector, Belgrade, Serbia

and more 47 locations